GnRH agonist | Trade names and availability | Dose, frequency, and method of administration |
Histrelin acetate subcutaneous implant | Supprelin LA (US) | Subcutaneous implant. Children ≥2 years – 50 mg implant surgically inserted every 12 months. Releases approximately 65 mcg per day over 12 months. |
Leuprolide acetate (leuprorelin) | 1-month formulations:
| Intramuscular depot injection, given every 28 days. Available strengths:
Typical starting dose is 7.5 mg but may vary among countries.¶ |
3-month formulations:
| Intramuscular depot injection, given every 3 months. Available strengths:
Criteria for selection of the 11.25 mg versus 30 mg dose have not been established. | |
6-month formulations:
| Subcutaneous injection (Fensolvi) or intramuscular depot injection (Lupron Depot-Ped). Available strength:
| |
Triptorelin pamoate | Gonapeptyl (UK, EU, SA, elsewhere) Decapeptyl (UK, elsewhere) Triptodur (US) | Intramuscular depot injections Available strengths:
|
GnRH: gonadotropin-releasing hormone; US: United States; SR: sustained-release; CAN: Canada; EU: European Union; UK: United Kingdom; AU: Australia; SA: South America.
* Strength not approved for treatment of central precocious puberty in the United States but may be approved elsewhere.
¶ In the United States, Canada, and some other countries, prescribing information includes higher starting doses for children weighing >25 kg, but some experts recommend against weight-based dosing[1].آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟